Related Experiment Videos
[Clinical studies of cefteram pivoxil in pediatric infection]
H Hirosawa1, Y Ishikawa, S Takahashi
1Department of Pediatrics, School of Medicine, Kyorin University.
Insights
The new antibiotic cefteram pivoxil (CFTM-PI) demonstrated high efficacy and safety in pediatric patients with various infections. With an 87.1% clinical efficacy and 92.0% bacterial eradication rate, CFTM-PI is a valuable pediatric treatment option.
Area of Science:
- Pediatric infectious diseases
- Pharmacology and therapeutics
- Antimicrobial resistance
Context:
- Cephem antibiotics are crucial for treating bacterial infections.
- Pediatric populations require specialized therapeutic approaches.
- Evaluating novel antibiotics like cefteram pivoxil (CFTM-PI) is essential for expanding treatment options.
Purpose:
- To assess the clinical utility and safety of cefteram pivoxil (CFTM-PI) in pediatric patients.
- To determine the efficacy of CFTM-PI in treating common pediatric infections.
- To evaluate the bacteriological response and adverse effects of CFTM-PI.
Summary:
- A study involving 31 pediatric patients (8 months to 8 years) treated with cefteram pivoxil (CFTM-PI) for acute infections.
- Patients received CFTM-PI orally at doses of 3.0-4.2 mg/kg, with treatment durations ranging from 3 to 13 days.
- Clinical efficacy was observed in 87.1% of patients, with a 92.0% bacterial eradication rate. No adverse reactions or laboratory abnormalities were reported.
Impact:
- Cefteram pivoxil (CFTM-PI) shows significant promise as a safe and effective antibiotic for pediatric infectious diseases.
- The findings support the use of CFTM-PI as a valuable therapeutic agent in pediatric practice.
- This study contributes to the evidence base for novel antibiotic பயன்பாடு in children.
Abstract:
The usefulness of a new cephem antibiotic, cefteram pivoxil (CFTM-PI, T-2588), was evaluated in the field of pediatrics. 1. Thirty-one patients were enrolled in the study. They included 20 boys and 11 girls with ages 8 months to 8 years 7 months. 2. The patients were treated with CFTM-PI at a dose levels ranging 3.0-4.2 mg/kg in 3 divided portions. The administration was done orally for a duration between 3 and 13 days, with a total dose between 27.3 and 130.0 mg/kg. 3. The patients were diagnostically classified into the following categories: 11 with acute pharyngitis, 1 with acute nasopharyngitis, 6 with acute tonsillitis, 9 with acute bronchitis, 2 with scarlet fever, 1 with purulent parotitis and 1 with purulent cervical lymphadenitis. 4. Clinical responses to the treatment were excellent in 14, good in 13, fair in 1 and poor in 3 patients with an overall efficacy rate of 87.1%. 5. Bacteriological responses were as follows: of 29 bacterial strains presumed to be pathogens, 23 were eradicated, 2 unchanged and 4 unknown, with an eradication rate of 92.0%. 6. Neither adverse reactions nor abnormal changes in laboratory test values were observed with the medication in any patients during and after the end of the treatment. None of the patients refused the medication. CFTM-PI was found very effective and safe in treating pediatric infections: it is a useful drug in the field of pediatrics.